Gerresheimer's $180M Georgia Gamble Overshadowed by Accounting Crisis

Gerresheimer opens automated warehouses in Georgia while facing IFRS violations, BaFin probe, and short-seller pressure. Key catalyst: audited 2024 report due June.

Deep in the pine forests of Peachtree City, Georgia, some 40 kilometers south of Atlanta, Gerresheimer is making a very different kind of bet. Two automated pallet warehouses, each 13 meters high and capable of holding 1,104 pallets, have just come online at the plant that churns out inhalers, autoinjectors, and infusion system components. The new software tracks more than 30 product categories, replacing manual processes that were already straining under the weight of a broader expansion. That expansion — a $180 million project launched in 2024 — adds roughly 17,900 square meters of cleanroom space and is expected to create over 400 jobs.

Back in Germany, the narrative could not be more different. Gerresheimer is still without a signed-off annual report for 2024, thanks to systematic IFRS violations that saw the company book revenue on goods invoiced but not yet delivered. An independent law firm confirmed that the misstatements hit €35 million in revenue and €24 million in adjusted EBITDA. The BaFin financial regulator has widened its probe, flagging potential reporting errors in several other line items. Meanwhile, the auditor oversight body APAS has opened a professional conduct case against KPMG, the firm that gave the 2024 accounts an unqualified audit opinion despite the irregularities.

Investors have taken notice — not always in the way management would hope. Short-seller Connor, Clark & Lunn Investment Management trimmed its net short position by roughly 14 percent on June 10, moving from 0.79 to 0.68 percent. But several other hedge funds maintain substantial bearish bets. The structural dynamics favor them: Gerresheimer was booted from the SDAX index in April 2026 as a direct consequence of the accounting crisis, meaning passive index funds no longer need to hold the stock — and some are actively selling.

The legal heat is also turning up. The Association for the Protection of Shareholders (DSW) has commissioned a report on the liability of former executives, specifically ex-CEO Dietmar Siemssen and ex-CFO Bernd Metzner. At stake is not just past conduct but also €676 million in goodwill that remains under review. DSW managing director Marc Tüngler has signaled that the more concrete claims become, the more likely a litigation funder will step in to bankroll lawsuits.

On the divestiture front, Gerresheimer's US subsidiary Centor Inc. — valued at €292 million on the balance sheet at the end of 2024 — is being shopped with Morgan Stanley running the sale process. A double-digit number of suitors are already kicking the tires, and management expects a deal to close before year-end. The proceeds would provide some financial breathing room, but the overarching condition for any recovery remains the delivery of an audited annual report, which the company aims to publish by the end of June.

That report is the single most important catalyst for the stock. Without it, many institutional investors simply cannot own the shares. And the 2026 outlook — revenue of €2.3–2.4 billion, an adjusted EBITDA margin of 18–19 percent, and moderately positive free cash flow — carries the explicit caveat “subject to a positive BaFin outcome.” That is the cloud that hangs over every forecast.

The share price has rallied hard from its February trough of €14.90, lately changing hands near €25.14. Yet that still marks a 45.7 percent decline over twelve months, a reminder of how far trust has eroded. Automated warehouses in Georgia and an audit signature in Düsseldorf are, for now, two different worlds connected only by the same troubled stock ticker.